China / SCLC . ANLOTINIB ( ORAL ) Plus Platinum-Etoposide As a First-Line Treatment For Extensive-Stage Small Cell Lung Cancer : A single-Arm Trial Provided An Effective And Safe Therapy For Patients With ES-SCLC / ... / También Hay Resultados Para Segunda Línea .

WILEY ONLINE LIBRARY - 8 May 2022 .

*.- The Primary Endpoint Was Progression-Free Survival (PFS) and Objective Response rate (ORR). 

*.- The Secondary Endpoints Included Overall Survival (OS), Disease Control Rate (DCR), Time to Progression (TTP), Duration of Remission (DoR), and Safety. 

*.- The Subgroups of Preset Liver Metastasis and Brain Metastasis Were Analyzed .

Results

In 35 ES-SCLC patients, the median PFS, ORR, DCR, and OS were 8.02 months [95% confidence interval (CI): 6.90–9.66], 85.71% (95% CI: 69.74–95.19), 94.29% (95% CI: 80.84–99.30), and 15.87 months (95% CI: 10.38–18.89), respectively. The median PFS in the liver metastasis and brain metastasis subgroups was 7.33 months (95% CI: 4.76–9.69) and 7.34 months (95% CI: 5.68–9.20), respectively. The most common AEs with grade 3–4 were hand–foot syndrome (17%), granulocytosis (17%), stomatitis (14%), hypertriglyceridemia (11%), hypercholesterolemia (11%), as well as nausea and vomiting (11%), and no grade 5 AEs were recorded.

Conclusions

Anlotinib Combined With Platinum-Etoposide Provided an Effective And Safe Therapy For Patients With ES-SCLC .

*********************************************

También Hay en Curso Ensayos Clínicos Para el Tratamiento de SCLC con Pacientes en Segunda Línea : ( Link : BUDDGL888&# ) : 

SCLC . ANLOTINIB ORAL . Se Va Posicionando Como Un Prometedor Fármaco Para el Tratamiento de Pacientes con Cáncer de Pulmón Microcítico en Segunda Línea ... Tanto en Monoterapia Como en Combinación .